[Form 4] Xylem Inc Insider Trading Activity

Rhea-AI Filing Summary

Stacy Cozad, SVP & Chief Legal Officer of Xylem Inc. (XYL), received equity awards on 09/02/2025. The filing reports 735 restricted stock units granted at an indicated price of $140.35 and 2,579 non-qualified stock options$140.35. The RSUs and options vest in three equal annual tranches on March 5, 2026, 2027 and 2028. After these transactions the filing shows 735 shares2,579 option-related shares

Insights

Corporate Governance Expert

TL;DR: Routine executive compensation grants to align management with shareholder interests; standard multi-year vesting schedule.

The Form 4 documents customary equity-based compensation for a senior executive: 735 restricted stock units and 2,579 non-qualified options with a vesting schedule in three equal tranches across 2026-2028 and an exercise price of $140.35. This is a common structure to retain executives and tie pay to future share performance. The filing is administrative and does not disclose additional context such as total outstanding dilution or grant rationale.

Securities Analyst

TL;DR: Non-material individual equity awards disclosed; no revenue, earnings, or material transaction data included.

The reported grants reflect compensation activity rather than operational or financial developments. The options expire in 2035 and are exercisable per the stated vesting dates. The filing provides exact quantities and prices but lacks information on aggregate company-level impact, so its investor impact is limited to disclosure of insider holdings and potential future dilution from these awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cozad Stacy

(Last) (First) (Middle)

C/O XYLEM INC.

301 WATER STREET SE

(Street)

WASHINGTON DC 20003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		735(1)	A	$140.35	735	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Options (Right to buy)	$140.35	09/02/2025		A		2,579		(2)	09/02/2035	Common Stock	2,579	$140.35	2,579	D

Explanation of Responses:

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 5, 2026, March 5, 2027 and March 5, 2028.

2. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 5, 2026, March 5, 2027 and March 5, 2028.

Remarks:

	/s/ Mike Nazario, by power of attorney for Stacy Cozad	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Stacy Cozad receive according to the XYL Form 4?

The Form 4 reports 735 restricted stock units and 2,579 non-qualified stock options granted on 09/02/2025.

What is the exercise price and vesting schedule for the options reported on the Form 4?

The options have an exercise price of $140.35, vest in three equal tranches on March 5, 2026, March 5, 2027, and March 5, 2028, and expire on 09/02/2035.

How many shares does the Form 4 show as beneficially owned after the reported transactions?

The filing shows 735 shares2,579 underlying shares

Who filed and signed the Form 4 for Stacy Cozad?

The Form 4 was signed by Mike Nazario by power of attorney for Stacy Cozad on 09/03/2025.